Granules India gets licence from DRDO to manufacture and market COVID-19 drug

Drug firm Granules India on Thursday said it has received licence from Defence Research & Development Organisation (DRDO) to manufacture and market COVID-19 treatment drug, 2- Deoxy-D-Glucose (2-DG).

migrator

Updated:2nd Sep, 2021 at 6:28 PM

New Delhi

Developed by DRDO, 2-DG has been granted permission by Drug Controller General of India (DCGI) for emergency use as adjunct therapy in moderate to severe COVID-19 patients, Granules India said in a filing to BSE.

''Granules is working closely with DRDO team to launch the product in India at the earliest,'' it added. The drug reduces a patient's average recovery time by two and half days and oxygen demand by up to 40 percent, the filing said. Shares of Granules India closed at Rs 344.20 per scrip on BSE, down 0.22 percent from the previous close.

Visit news.dtnext.in to explore our interactive epaper!

Download the DT Next app for more exciting features!

Click here for iOS

Click here for Android

Granules India gets licence from DRDO to manufacture and market COVID-19 drug

Drug firm Granules India on Thursday said it has received licence from Defence Research &amp; Development Organisation (DRDO) to manufacture and market COVID-19 treatment drug, 2- Deoxy-D-Glucose (2-DG).

Also Read

CM Vijay administers over one crore students take anti-drug pledge across Tamil Nadu

Centre's Mines Bill bid to grab states’ revenue: TNCC president Manickam Tagore

Madras HC warns of costs, PIL challenging dropping of AIADMK MLAs’ disqualification withdrawn

Is Parandur grounded? What about other options: Edappadi K Palaniswami

I don't cheat others with pocket photo gimmick, says O Panneerselvam

Drug firm Granules India on Thursday said it has received licence from Defence Research & Development Organisation (DRDO) to manufacture and market COVID-19 treatment drug, 2- Deoxy-D-Glucose (2-DG).